MedTrace Logo

RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

NCT05600218 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-11-07

No results posted yet for this study

Summary

This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.

The aim of this study answer the following questions:

* Changes in the mortality risk profile of these patients after treatment administration.
* Baseline characteristics of patients initiating Selexipag.
* Parameters used for risk stratification prior to treatment escalation.
* Events during follow-up.

No comparison group available

Conditions

Interventions

DRUG

No intervention - Observational study

Real life drug evaluation

Sponsors & Collaborators

  • Hospital Universitario Virgen Macarena

    collaborator OTHER

  • Hospital Regional de Malaga

    collaborator OTHER

  • Hospital Universitario Virgen de la Victoria

    collaborator OTHER

  • Hospital San Juan de la Cruz

    collaborator OTHER

  • Complejo Hospitalario de Especialidades Juan Ramón Jimenez

    collaborator OTHER

  • Hospitales Universitarios Virgen del Rocío

    collaborator OTHER

  • Hospital Clinico Universitario San Cecilio

    collaborator OTHER

  • Hospital Universitario de Valme

    collaborator OTHER

  • Hospital de Poniente

    collaborator UNKNOWN

  • Hospital Costa del Sol

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05600218 on ClinicalTrials.gov